Fideuram Intesa Sanpaolo Private Banking S.P.A. Takes $1.90 Million Position in BioMarin Pharmaceutical Inc. $BMRN

Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 31,991 shares of the biotechnology company’s stock, valued at approximately $1,901,000.

A number of other hedge funds have also recently made changes to their positions in the company. Viking Global Investors LP boosted its stake in shares of BioMarin Pharmaceutical by 13.8% during the second quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock valued at $675,505,000 after purchasing an additional 1,488,552 shares in the last quarter. AQR Capital Management LLC raised its position in shares of BioMarin Pharmaceutical by 6.3% during the third quarter. AQR Capital Management LLC now owns 5,932,109 shares of the biotechnology company’s stock worth $321,283,000 after acquiring an additional 351,536 shares during the last quarter. Capital Research Global Investors raised its position in shares of BioMarin Pharmaceutical by 547.5% during the third quarter. Capital Research Global Investors now owns 2,537,596 shares of the biotechnology company’s stock worth $137,436,000 after acquiring an additional 2,145,717 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of BioMarin Pharmaceutical by 42.7% during the third quarter. Dimensional Fund Advisors LP now owns 2,245,186 shares of the biotechnology company’s stock worth $121,597,000 after acquiring an additional 671,566 shares during the last quarter. Finally, Northern Trust Corp raised its position in shares of BioMarin Pharmaceutical by 0.4% during the third quarter. Northern Trust Corp now owns 1,662,268 shares of the biotechnology company’s stock worth $90,028,000 after acquiring an additional 7,157 shares during the last quarter. 98.71% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. The Goldman Sachs Group assumed coverage on BioMarin Pharmaceutical in a research report on Monday, May 11th. They set a “neutral” rating and a $69.00 price objective for the company. Sanford C. Bernstein lowered their price objective on BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating for the company in a research report on Tuesday, May 5th. Guggenheim lowered their price objective on BioMarin Pharmaceutical from $106.00 to $86.00 and set a “buy” rating for the company in a research report on Wednesday, February 25th. Oppenheimer lowered their price objective on BioMarin Pharmaceutical from $98.00 to $95.00 and set an “outperform” rating for the company in a research report on Tuesday, February 24th. Finally, Loop Capital set a $105.00 price objective on BioMarin Pharmaceutical in a research report on Monday, March 2nd. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $88.88.

BioMarin Pharmaceutical News Roundup

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin announced that its Phase 3 study of VOXZOGO (vosoritide) in children with hypochondroplasia met its primary endpoint, showing a statistically significant improvement in annualized growth velocity and supporting planned FDA and international filings in 2026. Article Title
• Positive Sentiment: Reuters reported the hypochondroplasia results helped drive shares higher in extended trading, reinforcing investor optimism that VOXZOGO could expand into another rare-disease indication and add to future growth. Article Title
• Positive Sentiment: Citigroup initiated coverage on BioMarin with a buy/strong-buy view, adding to the bullish tone around the stock. Article Title
• Neutral Sentiment: Several analyst roundups highlighted BioMarin among healthcare names being watched favorably, but these items were mostly commentary rather than new company-specific catalysts. Article Title
• Negative Sentiment: BioMarin also disclosed mixed Phase 3 results for BMN 401 in ENPP1 deficiency, with the trial meeting only one of two co-primary endpoints, which tempers the enthusiasm from the VOXZOGO news. Article Title

BioMarin Pharmaceutical Trading Up 7.8%

Shares of BMRN stock opened at $54.10 on Friday. The company has a market cap of $10.46 billion, a P/E ratio of 39.49, a PEG ratio of 0.38 and a beta of 0.23. The stock has a 50 day simple moving average of $54.69 and a two-hundred day simple moving average of $56.26. The company has a debt-to-equity ratio of 0.23, a quick ratio of 4.20 and a current ratio of 5.81. BioMarin Pharmaceutical Inc. has a fifty-two week low of $49.26 and a fifty-two week high of $66.28.

Insider Buying and Selling

In other BioMarin Pharmaceutical news, EVP Gregory R. Friberg sold 3,281 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $53.85, for a total value of $176,681.85. Following the completion of the sale, the executive vice president directly owned 51,818 shares in the company, valued at approximately $2,790,399.30. The trade was a 5.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Charles Greg Guyer sold 16,486 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $60.46, for a total value of $996,743.56. Following the completion of the sale, the executive vice president owned 79,953 shares of the company’s stock, valued at approximately $4,833,958.38. The trade was a 17.09% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 26,093 shares of company stock valued at $1,555,389. 0.85% of the stock is currently owned by corporate insiders.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.